[go: up one dir, main page]

PL3294719T3 - Piroglutaminian wortioksetyny - Google Patents

Piroglutaminian wortioksetyny

Info

Publication number
PL3294719T3
PL3294719T3 PL16721817T PL16721817T PL3294719T3 PL 3294719 T3 PL3294719 T3 PL 3294719T3 PL 16721817 T PL16721817 T PL 16721817T PL 16721817 T PL16721817 T PL 16721817T PL 3294719 T3 PL3294719 T3 PL 3294719T3
Authority
PL
Poland
Prior art keywords
vortioxetine pyroglutamate
vortioxetine
pyroglutamate
Prior art date
Application number
PL16721817T
Other languages
English (en)
Inventor
Heidi Lopez De Diego
Kim Lasse Christensen
Rene Holm
Jens Kateb
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55963369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3294719(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of PL3294719T3 publication Critical patent/PL3294719T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/282-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL16721817T 2015-05-13 2016-05-11 Piroglutaminian wortioksetyny PL3294719T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201500284 2015-05-13
PCT/EP2016/060540 WO2016180870A1 (en) 2015-05-13 2016-05-11 Vortioxetine pyroglutamate
EP16721817.1A EP3294719B1 (en) 2015-05-13 2016-05-11 Vortioxetine pyroglutamate

Publications (1)

Publication Number Publication Date
PL3294719T3 true PL3294719T3 (pl) 2019-04-30

Family

ID=55963369

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16721817T PL3294719T3 (pl) 2015-05-13 2016-05-11 Piroglutaminian wortioksetyny

Country Status (44)

Country Link
US (2) US10287261B2 (pl)
EP (1) EP3294719B1 (pl)
JP (1) JP6731001B2 (pl)
KR (1) KR102551429B1 (pl)
CN (1) CN107567440B (pl)
AR (1) AR104591A1 (pl)
AU (1) AU2016259762B2 (pl)
BR (1) BR112017024039B8 (pl)
CA (1) CA2984615C (pl)
CL (1) CL2017002844A1 (pl)
CO (1) CO2017011295A2 (pl)
CR (1) CR20170506A (pl)
CY (1) CY1121171T1 (pl)
DK (1) DK3294719T3 (pl)
DO (1) DOP2017000260A (pl)
EA (1) EA032363B1 (pl)
EC (1) ECSP17074919A (pl)
ES (1) ES2709362T3 (pl)
GE (1) GEP20197020B (pl)
HK (1) HK1252099B (pl)
HR (1) HRP20190089T1 (pl)
HU (1) HUE042893T2 (pl)
IL (1) IL255466B (pl)
JO (1) JO3456B1 (pl)
LT (1) LT3294719T (pl)
MA (1) MA43397A (pl)
ME (1) ME03312B (pl)
MX (1) MX375469B (pl)
MY (1) MY184965A (pl)
PE (1) PE20180039A1 (pl)
PH (1) PH12017502028A1 (pl)
PL (1) PL3294719T3 (pl)
PT (1) PT3294719T (pl)
RS (1) RS58263B1 (pl)
RU (1) RU2713889C2 (pl)
SI (1) SI3294719T1 (pl)
SM (1) SMT201900053T1 (pl)
SV (1) SV2017005560A (pl)
TN (1) TN2017000453A1 (pl)
TR (1) TR201901228T4 (pl)
TW (1) TWI700276B (pl)
UA (1) UA120779C2 (pl)
WO (1) WO2016180870A1 (pl)
ZA (1) ZA201707337B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018003930A2 (pt) 2016-07-01 2018-09-25 H Lundbeck As regimes de dosagem de vortioxetina para início rápido de efeito antidepressivo
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
EP3582759A4 (en) * 2017-02-17 2021-01-06 Unichem Laboratories Ltd BIOEQUIVALENT PHARMACEUTICAL COMPOSITION OF VORTIOXETINE BROMHYDRATE
CN111201217A (zh) * 2017-07-31 2020-05-26 斯玛尔药物有限公司 羟基去甲氯胺酮的晶型
GB201715950D0 (en) * 2017-10-02 2017-11-15 Croda Int Plc Gel composition comprising a phase change material
KR20220163997A (ko) 2020-04-03 2022-12-12 하. 룬드벡 아크티에셀스카브 정서적 둔마의 예방 또는 치료를 위한 1-[2-(2,4-디메틸페닐설파닐)-페닐]피페라진

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1006728A (en) * 1962-12-31 1965-10-06 Mundipharma Ag Amine salts of pyrrolidone carboxylic acid
JPS6160620A (ja) 1984-09-03 1986-03-28 Teijin Ltd ピログルタミン酸エステル類を含有する医薬品組成物
US4780667A (en) 1985-06-25 1988-10-25 Hewlett-Packard Company Magnetostatic wave delay line discriminator with automatic quadrature setting and automatic calibration
FR2694194B1 (fr) 1992-07-31 1994-11-04 Health Business Dev Gel hydratant, médicament et composition cosmétique le contenant, procédé de préparation dudit gel.
WO1998006385A1 (de) 1996-08-15 1998-02-19 Losan Pharma Gmbh Gut schluckbare orale arzneiform
US6436946B1 (en) * 1997-05-02 2002-08-20 Morris A. Mann Xanthine-containing compositions for oral administration and uses related thereto
SK284948B6 (sk) 2000-04-06 2006-03-02 Zentiva, A. S. Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DK1758557T3 (da) 2004-05-11 2011-10-24 Egalet Ltd Kvældbar doseringsform omfattende gellangummi
RS52205B2 (sr) * 2006-06-16 2021-05-31 H Lundbeck A/S 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazin kao jedinjenje sa kombinovanom aktivnošću ponovnog uzimanja serotonina, 5-ht3 i 5-ht1a, za tretman kognitivnih oštećenja
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
ES2512719T3 (es) * 2009-04-24 2014-10-24 H. Lundbeck A/S Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina
PL2470166T3 (pl) 2009-08-24 2013-11-29 H Lundbeck As Nowe kompozycje 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny
EP2564838A4 (en) 2010-04-30 2014-06-04 Takeda Pharmaceutical ENTERICIAN TABLET
CN104797566B (zh) * 2012-09-19 2017-07-07 桑多斯股份公司 沃替西汀氢溴酸盐的新结晶形式
ME02671B (me) 2013-02-22 2017-06-20 H Lundbeck As Postupak za proizvodnju vortioksetina

Also Published As

Publication number Publication date
CA2984615A1 (en) 2016-11-17
US20160368884A1 (en) 2016-12-22
IL255466B (en) 2022-07-01
ME03312B (me) 2019-10-20
DK3294719T3 (en) 2019-02-25
LT3294719T (lt) 2019-02-11
TR201901228T4 (tr) 2019-02-21
ECSP17074919A (es) 2018-02-28
EP3294719B1 (en) 2019-01-02
SI3294719T1 (sl) 2019-03-29
JP2018515520A (ja) 2018-06-14
MA43397A (fr) 2018-03-21
AR104591A1 (es) 2017-08-02
AU2016259762A1 (en) 2017-11-16
CN107567440A (zh) 2018-01-09
CA2984615C (en) 2023-06-13
RU2017139002A3 (pl) 2019-08-30
CR20170506A (es) 2018-02-08
PE20180039A1 (es) 2018-01-09
KR102551429B1 (ko) 2023-07-04
EP3294719A1 (en) 2018-03-21
DOP2017000260A (es) 2018-02-28
MX375469B (es) 2025-03-06
EA032363B1 (ru) 2019-05-31
HUE042893T2 (hu) 2019-07-29
AU2016259762B2 (en) 2020-03-19
CY1121171T1 (el) 2020-05-29
US10287261B2 (en) 2019-05-14
JP6731001B2 (ja) 2020-07-29
GEP20197020B (en) 2019-09-25
PT3294719T (pt) 2019-02-07
SMT201900053T1 (it) 2019-02-28
SV2017005560A (es) 2018-02-23
HK1252099A1 (zh) 2019-05-17
KR20180006909A (ko) 2018-01-19
ES2709362T3 (es) 2019-04-16
ZA201707337B (en) 2019-02-27
US11279682B2 (en) 2022-03-22
RS58263B1 (sr) 2019-03-29
MX2017014390A (es) 2018-03-23
TWI700276B (zh) 2020-08-01
HK1252099B (zh) 2020-02-07
PH12017502028A1 (en) 2018-04-02
CN107567440B (zh) 2021-06-22
CO2017011295A2 (es) 2018-02-20
UA120779C2 (uk) 2020-02-10
RU2713889C2 (ru) 2020-02-10
TN2017000453A1 (en) 2019-04-12
US20190210987A1 (en) 2019-07-11
IL255466A (en) 2018-01-31
WO2016180870A1 (en) 2016-11-17
JO3456B1 (ar) 2020-07-05
TW201706255A (zh) 2017-02-16
BR112017024039A2 (pt) 2018-07-24
MY184965A (en) 2021-04-30
RU2017139002A (ru) 2019-06-13
HRP20190089T1 (hr) 2019-02-22
EA201792262A1 (ru) 2018-04-30
BR112017024039B1 (pt) 2023-07-04
BR112017024039B8 (pt) 2023-10-31
CL2017002844A1 (es) 2018-05-11

Similar Documents

Publication Publication Date Title
DK3250592T3 (en) Anti-transthyretin-antistoffer
SG10201912505YA (en) Exosuit
HRP20190089T1 (hr) Vortioksetin piroglutamat
HK1251001A1 (zh) Il-37變體
GB201513158D0 (en) Microdosimeter
AU361999S (en) Ballustrade
HUE057130T2 (hu) Csírátlanító
DK3282866T3 (en) Proteinfibre
LT3393990T (lt) Peg rišiklis
GB201514649D0 (en) 2-Sulfonylpyrimidines
GB201522365D0 (en) Concept abcd12
GB201518520D0 (en) Concept ABCD4
GB201521340D0 (en) Snapshop
GB201515216D0 (en) Concept B
GB201515187D0 (en) Kerbie
PH32015000731S1 (en) Quadricycle
GB201506176D0 (en) Concept concept
GB201511795D0 (en) CeltOme
GB201501123D0 (en) Concept E
AU2015165V (en) PWBC12 Chamelaucium uncinatum
AU362754S (en) Playsuit
GB201510075D0 (en) Projectorch
GB201509898D0 (en) Lookma
AU2015212V (en) SGIPU2-0 Scabiosa columbaria
AU2015211V (en) SGIBL01-0 Scabiosa columbaria